Median progression-free survival was 7.6 months with the combination versus 5.4 with chemotherapy; results were presented at ...

Murray brings more than three decades in financial technology, including leadership at FIS, and will deepen client ...

KRAS mutations affect about 40% of colorectal cancers, and G12D is the most common. Genmab will conduct the study; Incyte ...

The 56% response rate came from 25 patients with CEA-high tumors; BeOne intends to advance both lung programs toward ...

The officers and directors of a company whose stock is registered with the SEC, and anyone who owns more than 10% of a registered class of its stock, file a Form 4 when their holdings change. A few ...

Study patients had high-grade serous, platinum-resistant ovarian cancer and a median of four prior lines of therapy. Call ...

PRAME-high melanoma: 12.5-month median response duration; 91% alive at one year. First data on IMA402 with IMA401 in lung cancer are expected in 2027.

Options carry a $5.02 exercise price, equal to the Oct. 23 closing price; restricted stock unit grants are expected around ...

The estimate is entirely inferred: 4.00% zinc, 2.77% lead and 20.37 g/t silver; mineral resources are not reserves and lack demonstrated economic viability.

The analysis included 295 people and found reductions in all four urinary markers, adding evidence FILSPARI may affect ...

The call begins at 4:30 p.m. Eastern; an online replay will be available about two hours later, and audio replay access runs ...

19.28% of eligible shareholders were present; other matters won over 96% approval, including the proposed auditor appointment ...